Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 90617, held by Dr Reddys Labs Ltd. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 90617 (Metoprolol Succinate), held by Dr Reddys Labs Ltd, was first approved by FDA on Aug 1, 2012, with 5 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets are a beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 1, 2012 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| May 9, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 9, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 16, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 27, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 27, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 1, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters